IL13 and Alzheimer disease: While targeted biologic therapies like dupilumab (an IL-4Rα inhibitor) and tralokinumab (an IL-13 inhibitor) have substantially decreased the disease burden for many patients with moderate-to-severe AD, some still struggle to achieve a desired level of disease control [1,9,11].